TITLE

AZT: Prolonging Life But Not Stopping Death

AUTHOR(S)
Helquist, Michael
PUB. DATE
March 1987
SOURCE
Advocate;3/3/87, Issue 467, p23
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reports that the medical advisers of the U.S. Food and Drug Administration have recommended in 1987 the licensing of AZT for sale to a restricted group of patients with AIDS or severe ARC. Initial results of studies on AZT; Benefits from taking AZT; Researchers' concerns about side effects.
ACCESSION #
9501244

 

Related Articles

  • New Report on AZT. Helquist, Michael // Advocate;1/17/89, Issue 516, p30 

    Reports on a study indicating that azidothymidine (AZT) can reverse the deterioration in mental and cognitive capabilities often experienced by individuals with AIDS or AIDS-related complex. Support for anecdotal reports on the benefits of the antiviral drug; Details of the study.

  • Drug Combo Update. Helquist, Michael // Advocate;10/29/85, Issue 432, p23 

    Reports on the effectiveness of using two drugs, isoprinosine and ribavirin to treat AIDS and AIDS-related complex. Existing practice of administering the drugs to patients; Mechanism of treatment; Implications for AIDS treatment.

  • Low Toxicity Reported With AIDS Drug CS-85. Helquist, Michael // Advocate;1/6/87, Issue 463, p23 

    Reports that the drug AZT continues to be a focal point for the hopes of people infected with HIV and those diagnosed with AIDS. Emphasis made on the lower mortality rate associated with the drug; Inhibition of the growth of the HIV.

  • The AZT fire storm. Gallagher, John // Advocate;5/18/93, Issue 629, p29 

    Reports on the controversy surrounding the effectiveness of AZT in the treatment of AIDS. Article published in a medical journal claiming that the antiviral drug may not slow the onset of AIDS in HIV-infected persons; Reaction of AIDS activists.

  • AZT is shit. Kramer, Larry // Advocate;5/18/93, Issue 629, p80 

    Focuses on the ineffectiveness of AZT in the treatment of AIDS. Criticism on concerned agencies for failure to discover and produce AIDS drugs; Government budget for AIDS research.

  • Timing of AZT. M.O.R. // Cortlandt Forum;03/25/97, Vol. 10 Issue 3, p139 

    Warns against the use of zidovudine monotherapy in newly diagnosed HIV patients. Drugs which could be combined with zidovudine to increase anti-HIV activity; Factors on which decisions about when to initiate treatment are usually based.

  • AZT Summary. Helquist, Michael // Advocate;4/28/87, Issue 471, p23 

    Discusses issues related to AZT, the first AIDS drug licensed by the U.S. Food and Drug Administration. Marketing of the drug under the brand name Retrovir; Limited supplies of the drug; Recommended dosage.

  • No Time to Relax. Helquist, Michael // Advocate;4/28/87, Issue 471, p23 

    Focuses on licenses for the AIDS drug AZT or Retrovir in the U.S., Great Britain and France. Hope given to people infected with HIV; Criticism on the limited availability of the drug; Flaws in the American health care system and the government's response to AIDS research.

  • Optimism about New Drug. Helquist, Michael // Advocate;3/4/86, Issue 441, p23 

    Highlights the results of a small-scale clinical trial of azidothymidine. Efficacy of the drug in preventing the AIDS virus from reproducing in the body; Need for more extensive studies.

Share

Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics